AstraZeneca and Oracle plan AI clinical research in Abu Dhabi

AstraZeneca and Oracle have signed a nonbinding agreement to explore using artificial intelligence and health data to improve clinical research and connect research findings with patient care, the companies said Tuesday. Their first planned project would focus on hypertension care and research in Abu Dhabi, in partnership with healthcare company M42. The companies intend to investigate whether AI and real-world health data can help clinicians identify people who may qualify for clinical trials, accelerate evidence generation and bring relevant research insights into routine care. The announcement describes proposed uses, not a completed deployment or demonstrated improvement in trial recruitment or patient outcomes. In Abu Dhabi, the planned programme would help clinical teams identify people with uncontrolled high blood pressure, support care in line with clinical guidelines and improve recruitment for trials, according to AstraZeneca. No launch date was given. The collaboration could explore a range of disease areas, including cancer, cardiovascular, renal and metabolic conditions, respiratory and immune diseases, and rare diseases. The companies also described the effort as...